BERKELEY, Calif., and VANCOUVER, British Columbia, September 9, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has upsized and closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company. Under …

BERKELEY, Calif., and VANCOUVER, British Columbia, August 27, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced it will be featured as a presenting company at the 21st Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright …

BERKELEY, Calif., and VANCOUVER, British Columbia, August 12, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that it has appointed Mr. Richard J. Berman, JD, MBA, to its Board of Directors. Mr. Berman is a highly experienced corporate …

BERKELEY, Calif., and VANCOUVER, British Columbia, July 23, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it intends to complete a non-brokered private placement of up to 5,000,000 common shares of the Company at a …

BERKELEY, Calif., and VANCOUVER, British Columbia, April 23, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings will be published in the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings, a supplement to …

• As presented at the American Association for Cancer Research (AACR) annual meeting: early efficacy data for the first six advanced breast cancer patients dosed with Bria-IMT™ in combination with KEYTRUDA® suggest additive or synergistic effects on tumor regression (“shrinkage”). • Findings support BriaCell’s hypothesis: KEYTRUDA® acts by “awakening” a component of the immune system, …

· BriaCell Therapeutics and Incyte have formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates · Under the agreement, Incyte will provide compounds from its development portfolio, including INCMGA00012, an anti-PD-1 monoclonal antibody, and epacadostat, an IDO1 inhibitor, for use in combination studies with BriaCell’s lead candidate, Bria-IMT™, …

BERKELEY, Calif., and VANCOUVER, British Columbia, April 1, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has upsized and closed the second and final tranche of its previously-announced non-brokered private placement (the “Second Tranche”) of common shares …